Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

~ Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity ~ 93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process ~ Key opinion leader webinar on Tuesday, June 15, 2021, at 1 p.m. ET

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here